Exploring MyMD Pharmaceuticals, Inc. (MYMD) Investor Profile: Who’s Buying and Why?

Curious who's buying into MyMD Pharmaceuticals, Inc. (MYMD) and why this tiny biotech keeps drawing attention? At a current share price of $1.82 (up $0.01 / 0.01% from the prior close) with an opening price of $1.79, intraday high of $1.83, low of $1.79 and volume of 24,349 as of Tuesday, July 23, 17:15:00 PDT, the stock sits within a concentrated ownership landscape: institutional investors held roughly 9.64% of shares and individual investors about 2.12% as of July 2024, while the largest single stakeholder, Mirae Asset Global Investments Co., Ltd., commands 40.6% of the company and the top 25 shareholders collectively own 54.48%; notable moves include PharmaCyte Biotech's strategic $7 million investment in May 2024 backing MyMD's TNF‑alpha inhibitor focus, Iroquois Capital trimming its stake from 9.56% to 6.47% between Feb 2022 and Feb 2023, Caroline Williams holding 5.78%, BlackRock at 0.50% (with a 0.94% uptick last quarter), Director Billy Joe White adding 22,839 shares in November 2025, MyMD regaining Nasdaq minimum bid compliance in March 2024, and a modest market capitalization of approximately $4.31 million as of July 2024-details that frame investor sentiment and strategic positioning worth unpacking in the full article

MyMD Pharmaceuticals, Inc. (MYMD) - Who Invests in MyMD Pharmaceuticals, Inc. (MYMD) and Why?

• Short-term traders - attracted by low per-share price and visible intraday volatility (range 1.79-1.83 USD on the cited day).
• Retail investors - small-position buyers seeking exposure to biotech/therapeutics upside with limited capital outlay.
• Speculative investors - event-driven players anticipating trial updates, licensing deals, or partnership announcements.

• The stock's low absolute price (1.82 USD) often increases the share count affordability for retail accounts and options positioning.
• Relatively light intraday volume (24,349) implies that significant buy or sell orders can move the price more sharply than for large-cap names.

• Upside from clinical or commercial news - biotech equities like MyMD are priced for binary news events; a positive development can trigger outsized gains relative to the current price.
• Portfolio diversification into small-cap biotech - some investors allocate a small percentage of capital to higher-volatility drug developers.
• Tax/lot strategies - low-cost lots can be easy to trim or realize losses/gains for tax management in retail portfolios.

MyMD Pharmaceuticals, Inc. (MYMD) Institutional Ownership and Major Shareholders of MyMD Pharmaceuticals, Inc. (MYMD)

• Institutional Investors: ~9.64% of shares held (as of July 2024), indicating modest institutional interest relative to peers in biotech.
• Individual (Retail) Investors: ~2.12% ownership (as of July 2024), a relatively small retail base.
• Largest Single Shareholder: Mirae Asset Global Investments Co., Ltd. - 40.6% ownership (major controlling stake).
• Insider Holdings: Caroline Williams - 5.78% ownership, signaling meaningful insider alignment.
• Strategic Investment: PharmaCyte Biotech, Inc. invested $7 million in May 2024, reflecting external confidence in MYMD's TNF-alpha inhibitor development strategy.
• Insider Transactions: Director Billy Joe White increased his holdings by 22,839 shares in November 2025, a notable insider purchase demonstrating confidence.
• Market Capitalization: Approximately $4.31 million (as of July 2024), underscoring a micro‑cap biotech profile.

• Why institutions might invest: concentrated exposure, potential upside from clinical progress in TNF-alpha inhibitors, strategic partnership opportunities.
• Why insiders buy: demonstrated insider buy (Billy Joe White) and sizable insider holding by Caroline Williams suggest management confidence in near‑term development or value realization.
• Risks for new investors: very low market cap (~$4.31M) and limited retail/institutional liquidity can amplify share price volatility.

MyMD Pharmaceuticals, Inc. (MYMD) - Key Investors and Their Impact on MyMD Pharmaceuticals, Inc. (MYMD)

• Top shareholder concentration: The top 25 shareholders collectively own 54.48% of the company, creating a tightly held register that can materially affect governance and strategic outcomes.
• Largest single holder: Mirae Asset Global Investments Co., Ltd. controls 40.6% of shares, making it the dominant strategic/investment influencer.
• Notable individual holder: Caroline Williams holds 5.78%, representing the largest named individual position.

• Governance impact: With Mirae Asset at 40.6% and top 25 holders at 54.48%, major holders can heavily influence board elections, strategic initiatives, and capital decisions.
• Liquidity and float considerations: Low institutional ownership (9.64%) and concentrated stakes can limit free-float liquidity and amplify price moves on block trades or directional buys/sells.
• Insider signaling: Director purchases (e.g., Billy Joe White, Nov 2025) are regulatory-visible signals that investors often monitor for confidence cues.

MyMD Pharmaceuticals, Inc. (MYMD) - Market Impact and Investor Sentiment

• Largest shareholder: Mirae Asset Global Investments Co., Ltd. holds 40.6% of shares, giving it substantial influence over corporate decisions and voting outcomes.
• Strategic biotech vote of confidence: PharmaCyte Biotech invested $7.0 million in May 2024, signaling sector-aligned confidence in MyMD's TNF-alpha inhibitor therapeutic focus.
• Insider holdings: Caroline Williams holds 5.78%, a sizable personal stake that aligns executive/insider interests with shareholders.
• Recent insider buying: Billy Joe White increased holdings by 22,839 shares in November 2025, indicating renewed insider confidence.
• Hedge/fund activity: Iroquois Capital Management reduced its stake from 9.56% (Feb 2022) to 6.47% (Feb 2023), reflecting partial deleveraging or reallocation over that period.
• Large-cap interest: BlackRock holds 0.50% of shares and increased its position by 0.94% in the most recent quarter, showing cautious institutional participation.

• Concentration risk: Mirae's 40.6% stake can compress float and magnify price moves on news or insider transactions.
• Sector validation: PharmaCyte's $7M investment reinforces MyMD's therapeutic thesis around TNF-alpha inhibitors, potentially aiding partner and investor confidence.
• Insider alignment: Combined insider stakes (Caroline Williams and Billy Joe White activity) suggest aligned management incentives and potential signal of confidence to retail investors.
• Institutional nuance: Iroquois's stake reduction and BlackRock's modest increase reflect mixed institutional views-some profit-taking or reallocation, others cautiously adding exposure.